Furthermore, there are phase II studies evaluate cabozantinib to treat recurrent HCC after liver transplantation (NCT04204850) or as second- or third-line treatment in HCC patients that progress on or are intolerant to immune checkpoint inhibitors, including anti-PD-1 and anti-PD-L1 antibodies (NCT04435977). This evidence concerns the gene CD274 and hepatocellular carcinoma.